# Regulatory Update: Diphenidine Placement in Schedule I > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/diphenidine-regulatory-scheduling-update-schedule-i/ > **Published:** 2026-06-12T08:23:19-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:04:58-04:00 > **Clinical Summary:** Explore the latest diphenidine regulatory scheduling update placing it in Schedule I due to abuse potential and lack of medical use. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. βš’ Policy Watch Β |Β  Federal Register cannabis_policyfederal_lawDEA_schedulingcontrolled_substancesdiphenidine_schedule_Istate_regulationmarijuana_legislation Clinical Summary The Drug Enforcement Administration has moved to place diphenidine, a synthetic dissociative drug, into Schedule I of the [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) Act due to its high abuse potential and lack of accepted medical use. Diphenidine is a designer drug that mimics the effects of established dissociatives like phencyclidine and ketamine, producing altered mental states and potential for psychological and physical dependence. This regulatory action addresses an emerging [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) concern as illicit diphenidine use has been documented in multiple states, often marketed as a legal alternative to controlled dissociatives. While diphenidine itself is not cannabis, this scheduling decision reflects the broader regulatory environment in which cannabinoid products operate and underscores how authorities continuously evaluate novel psychoactive substances for safety and abuse liability. Clinicians should be aware that patients may seek or use synthetic alternatives when preferred substances face legal restrictions, making clinical vigilance for novel drug use patterns important when assessing [substance use](https://cedclinic.com/stroke-risk-assessment-substance-use/) histories. For practitioners involved in cannabis-based therapeutics, this action demonstrates that regulatory agencies remain active in controlling dissociative and psychoactive compounds, which has implications for how cannabinoid products are positioned and regulated in the therapeutic landscape. Clinical Perspective 🧠 The DEA’s scheduling of diphenidine in Schedule I reflects ongoing regulatory efforts to control novel psychoactive substances (NPS) that evade existing drug laws, though clinicians should recognize this action provides limited direct guidance for managing patients already exposed to such compounds. Diphenidine, a dissociative analog of diphenhydramine with potential for abuse, shares structural and pharmacological similarities with other scheduled dissociatives, yet the heterogeneity of NPS means that scheduling one compound does nothing to prevent the emergence of structurally similar alternatives in the [illicit market](https://cedclinic.com/illicit-cannabis-market-risks-columbia-county-seizure/). Clinical encounters with patients using diphenidine or related novel dissociatives are complicated by the lack of established toxidromes, validated screening assays, or treatment protocols specific to these agents, making reliance on [supportive care](https://cedclinic.com/pediatric-oncology-supportive-care-cannabis-research-funding-iowa/) principles and poison control consultation essential. Importantly, rapid scheduling does not address the social, economic, or medical vulnerabilities that drive πŸ’¬ Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan β†’](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion β†’](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Placement+of+Diphenidine+in+Schedule+I+%40drcaplan&url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F26%2F2026-10380%2Fschedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F26%2F2026-10380%2Fschedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i)[πŸ¦… Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Placement+of+Diphenidine+in+Schedule+I+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F05%2F26%2F2026-10380%2Fschedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i)[πŸ“· Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[πŸ“ Read more on Substack](https://doctorapprovedcannabis.substack.com/)[πŸ”” Subscribe via RSS](https://cedclinic.com/feed/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) Related Articles - [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) - [Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://cedclinic.com/synthetic-ketamine-analog-regulation-temporary-scheduling/) - [FDA Cannabis Products Move from Schedule I to Schedule III Under New DEA Rule](https://cedclinic.com/cannabis-schedule-iii-reclassification-fda-approved-products/) πŸ“° Source: [https://www.federalregister.gov/documents/2026/05/26/2026-10380/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i](https://www.federalregister.gov/documents/2026/05/26/2026-10380/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) Review the scheduling of CUMYL-PEGACLONE as a Schedule I substance and its regulatory impact. [Read More](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) [Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I](https://cedclinic.com/dea-synthetic-ketamine-analog-control-2-fdck-schedule-i/) Explore the temporary scheduling of 2-Fluorodeschloroketamine and its implications for controlled substance regulation. [Learn More](https://cedclinic.com/dea-synthetic-ketamine-analog-control-2-fdck-schedule-i/) [Schedules of Controlled Substances: Rescheduling of FDA Approved Marijuana Products](https://cedclinic.com/dea-cannabis-rescheduling-proposal-schedule-i-to-iii/) Understand the rescheduling of FDA-approved marijuana products from Schedule I to Schedule III and related permit changes. [Discover More](https://cedclinic.com/dea-cannabis-rescheduling-proposal-schedule-i-to-iii/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR Β§ 164.514(b)) and criteria for secondary research exemption under 45 CFR Β§ 46.104(d)(4).